drug_type
RELEVANT_DRUG
intervention_type
Cellular therapy (TCR-T)
drug_description
Autologous TCR-engineered T cell therapy (TCR-T) in which a patient’s T cells are transduced with a high-affinity T-cell receptor recognizing KRAS G12V peptide presented by HLA-A*11:01, enabling antigen-specific cytotoxic killing of tumor cells.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Immunotherapy, Adoptive
drug_category
ENGINEERED TCR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous T cells are genetically engineered to express a high‑affinity TCR specific for the KRAS G12V peptide presented by HLA‑A*11:01 on tumor cells; upon infusion they recognize peptide–MHC I, activate via TCR signaling, and execute antigen‑specific cytotoxic killing via perforin/granzyme pathways (with lymphodepletion and IL‑2 support to enhance expansion).
drug_name
NW-301V
nct_id_drug_ref
NCT06484790